XBiotech, Inc. (XBIT) Loss Submission Form

Levi & Korsinsky has commenced the class action Price v. XBiotech, Inc., et al. (Case No. 1:17-cv-01023) in the USDC for the Western District of Texas, Austin Division on behalf of XBiotech shareholders who purchased shares between April 15, 2015 and April 20, 2017.

The complaint alleges that throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) the results of its European Phase III trial for the treatment of colorectal cancer with Xilonix were inconclusive; (2) the Company misrepresented the endpoint used in the European Study; (3) the Company’s claim of a 76% increase in improvement was misleading and represented a relative improvement rate; (4) ultimately, the Companies’ studies would not support the approval of the application with the EMA; and (5) as a result of the foregoing, Defendants’ statements about its business and operations were materially false and misleading at all relevant times.

If you suffered a loss in XBiotech you have until December 26, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

To receive more information, please fill out the form.

Levi & Korsinsky, LLP doesn't share your information with others. There is no cost or obligation to submit. Your submission does NOT establish an attorney-client relationship.

This submission does not create an attorney-client relationship. If we believe that you might be an appropriate lead plaintiff, we will contact you to discuss whether to establish an attorney-client relationship.